GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

SBFM · Jun 30, 2026

Sunshine Biopharma Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]

Inspectable configuration

State dimensions

Filing0001683168-26-006340General Corporate

Capex intensity21thOwn-history percentile · N=14

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.08% · OPTIONAL · VALID

Operating cash generation90thOwn-history percentile · N=20

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-9.91% · OPTIONAL · VALID

Revenue growth5thOwn-history percentile · N=20

Evidence method

Yoy · gp.fundamentals.revenue

-1.56% · CORE · VALID

Inventory pressure60thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

130.85% · OPTIONAL · VALID

Gross margin5thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.gross_margin

26.20% · CORE · VALID

Operating margin60thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.operating_margin

-17.41% · CORE · VALID

R&D intensity0thOwn-history percentile · N=20

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

0.14% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History30 statesSelf-history eligible

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 0.06%
Current: 0.08%
Delta: 0.01%

Cash Generation Increased

Previous: -25.62%
Current: -9.91%
Delta: 15.71%

Growth Increased

Previous: -9.13%
Current: -1.56%
Delta: 7.57%

Inventory Pressure Decreased

Previous: 162.80%
Current: 130.85%
Delta: -31.95%

Margin Decreased

Previous: 26.96%
Current: 26.20%
Delta: -0.77%

Profitability Decreased

Previous: -17.25%
Current: -17.41%
Delta: -0.16%

R And D Intensity Decreased

Previous: 0.39%
Current: 0.14%
Delta: -0.25%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Mar 31, 2025

Similarity: 88%
Compared: 7 dimensions
Coverage: 100%

Growth 5.0 · Margin 5.0 · Profitability 25.0 · Capex Intensity 0.8 · Cash Generation 0.0 · R And D Intensity 15.0 · Inventory Pressure 10.0

Mar 31, 2024

Similarity: 86%
Compared: 6 dimensions
Coverage: 86%

Growth 5.0 · Margin 0.6 · Profitability 28.9 · Cash Generation 6.7 · R And D Intensity 11.8 · Inventory Pressure 10.0

Jun 30, 2022

Similarity: 84%
Compared: 6 dimensions
Coverage: 86%

Growth 7.5 · Margin 22.3 · Profitability 21.8 · Cash Generation 0.9 · R And D Intensity 20.0 · Inventory Pressure 4.4

Mar 31, 2026

Similarity: 84%
Compared: 7 dimensions
Coverage: 100%

Growth 5.0 · Margin 0.0 · Profitability 5.0 · Capex Intensity 6.0 · Cash Generation 20.0 · R And D Intensity 0.0 · Inventory Pressure 35.0

Sep 30, 2024

Similarity: 84%
Compared: 6 dimensions
Coverage: 86%

Growth 5.0 · Margin 15.0 · Profitability 35.0 · Cash Generation 5.0 · R And D Intensity 10.5 · Inventory Pressure 1.1

Research Graph

Related governed research

Analogous To · SBFM state analogue 5 →Analogous To · SBFM state analogue 1 →Analogous To · SBFM state analogue 2 →Analogous To · SBFM state analogue 4 →Compared To · Pharmaceutical Preparations peers →Analogous To · SBFM state analogue 3 →Transitioned To · SBFM Fundamental State →Transitioned To · SBFM CAPEX_INTENSITY_INCREASED →Transitioned To · SBFM CASH_GENERATION_INCREASED →Transitioned To · SBFM GROWTH_INCREASED →Transitioned To · SBFM INVENTORY_PRESSURE_DECREASED →Transitioned To · SBFM MARGIN_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.